Transgene: Significant milestones achieved on all drug candidates in 2020 and financial visibility until 2022
information fournie par Boursorama CP 10/03/2021 à 17:45
2020 Full-year results and business update
- TG4050: first patients treated in two clinical trials of the novel individualized immunotherapy based on the myvac® technology - First data expected in 4Q 2021
- TG4001: expanded randomized Phase II trial to start in HPV-positive anogenital cancers, based on encouraging Phase Ib/II data
- BT-001: the first candidate from the Invir.IO(TM) platform has entered the clinic
- Financial visibility until 2022 following the partial sale of the stake in Tasly BioPharmaceuticals in 2020
Conference call in English scheduled today at 6:00 p.m. CET - Video conference in French on March 10 at 10:00 a.m. CET (details at the end of the release)
.../...